BlackRock Inc. lowered its holdings in Nantkwest Inc (NASDAQ:NK) by 1.4% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 2,549,061 shares of the biotechnology company’s stock after selling 36,454 shares during the quarter. BlackRock Inc. owned about 3.22% of Nantkwest worth $7,801,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also added to or reduced their stakes in NK. JPMorgan Chase & Co. increased its position in Nantkwest by 40.9% during the 1st quarter. JPMorgan Chase & Co. now owns 46,068 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 13,366 shares during the period. A.R.T. Advisors LLC purchased a new position in Nantkwest during the 1st quarter valued at $119,000. Millennium Management LLC boosted its holdings in shares of Nantkwest by 402.4% during the 1st quarter. Millennium Management LLC now owns 156,744 shares of the biotechnology company’s stock valued at $610,000 after buying an additional 125,544 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Nantkwest by 40.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 170,271 shares of the biotechnology company’s stock valued at $521,000 after buying an additional 49,040 shares in the last quarter. Institutional investors and hedge funds own 13.55% of the company’s stock.
A number of brokerages have recently commented on NK. ValuEngine upgraded shares of Nantkwest from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Citigroup cut shares of Nantkwest to a “hold” rating and set a $3.00 target price on the stock. in a report on Friday, August 10th. Zacks Investment Research upgraded shares of Nantkwest from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Wednesday, October 10th. Finally, BidaskClub upgraded shares of Nantkwest from a “sell” rating to a “hold” rating in a report on Friday, September 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $3.63.
In related news, Director Steve Gorlin sold 50,000 shares of the company’s stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $3.07, for a total value of $153,500.00. Following the transaction, the director now owns 224,805 shares in the company, valued at approximately $690,151.35. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 72.30% of the company’s stock.
Shares of NK stock opened at $2.65 on Wednesday. Nantkwest Inc has a 12 month low of $2.16 and a 12 month high of $5.47. The firm has a market cap of $193.27 million, a PE ratio of -2.21 and a beta of 3.16. The company has a current ratio of 5.45, a quick ratio of 5.45 and a debt-to-equity ratio of 0.03.
WARNING: “Nantkwest Inc (NK) Stake Lowered by BlackRock Inc.” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/11/07/nantkwest-inc-nk-stake-lowered-by-blackrock-inc.html.
NantKwest, Inc engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S.
Read More: Price to Earnings Ratio (PE), For Valuing Stocks
Want to see what other hedge funds are holding NK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nantkwest Inc (NASDAQ:NK).
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.